Johan Bratt

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial

Ronald van Vollenhoven, Sofia Ernestam, P. Geborek et al. · The Lancet · 2009 · 317 citations

Medicine, Clinical Sciences, Pharmacotherapy +10

Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial

Ronald van Vollenhoven, Pierre Geborek, Kristina Forslind et al. · The Lancet · 2012 · 225 citations

Medicine, Clinical Sciences, Pharmacotherapy +9

Predictors of response to methotrexate in early DMARD naïve rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial

Saedís Saevarsdóttir, Helena Wallin, Maria Seddighzadeh et al. · Annals of the Rheumatic Diseases · 2010 · 195 citations

Medicine, Internal Medicine, Pharmacotherapy +15

Adalimumab (Humira®) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade®) or etanercept (Enbrel®): results from the STURE registry at Karolinska University Hospital

Marius C. Wick, Sofia Ernestam, Staffan Lindblad et al. · Scandinavian Journal of Rheumatology · 2005 · 119 citations

Medicine, Pharmacology, Pharmacotherapy +16

In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial

Hamed Rezaei, Saedís Saevarsdóttir, Kristina Forslind et al. · Annals of the Rheumatic Diseases · 2011 · 96 citations

Medicine, Clinical Sciences, Pharmacotherapy +12